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T helper 17 (Th17) cells protect against infection
but also promote inflammation and autoimmunity.
Therefore, the factors that govern Th17 cell differen-
tiation are of special interest. The CD27 and CD70
costimulatory pathway impeded Th17 effector cell
differentiation and associated autoimmunity in a
mouse model of multiple sclerosis. CD27 or CD70
deficiency exacerbated disease, whereas constitu-
tive CD27 signaling strongly reduced disease inci-
dence and severity. CD27 signaling did not impact
master regulators of T helper cell lineage commit-
ment but selectively repressed transcription of the
key effector molecules interleukin-17 (IL-17) and the
chemokine receptor CCR6 in differentiating Th17
cells. CD27 mediated this repression at least in part
via the c-Jun N-terminal kinase (JNK) pathway that
restrained IL-17 and CCR6 expression in differenti-
ating Th17 cells. CD27 signaling also resulted in
epigenetic silencing of the Il17a gene. Thus, CD27
costimulation via JNK signaling, transcriptional, and
epigenetic effects suppresses Th17 effector cell
function and associated pathological consequences.
INTRODUCTION
Immunity to the vast array of pathogens that confront us requires
distinct T helper (Th) effector cell populations with dedicated
functions. Clearance of intracellular viral and bacterial infections
relies on Th1 cells, elimination of extracellular pathogens
requires Th2 cells, and defense against fungi and extracellular
bacteria depends on Th17 cells (Korn et al., 2009; Littman and
Rudensky, 2010). These different Th cell populations combat
infection by virtue of the specific cytokines they secrete: Th1
cells make interferon-g (IFN-g) and stimulate the cytotoxic
T cell response, whereas Th2 cells produce interleukin 4 (IL-4)
and IL-13 and stimulate antibody production. Th17 cells produceIL-17, IL-17F, and IL-22, which promote neutrophilia, tissue
repair, and the production of antimicrobial proteins (Korn et al.,
2009; Littman and Rudensky, 2010).
Th cells are beneficial for pathogen clearance, but they can
also contribute to tissue damage. Th17 cells in particular are
implicated in various human inflammatory and autoimmune
diseases, including Crohn’s disease, psoriasis, multiple scle-
rosis, and rheumatoid arthritis (Korn et al., 2009; Littman and
Rudensky, 2010). Studies in mice have also revealed causal
relationships between Th17 cells and the development of
these diseases. Particularly in experimental autoimmune
encephalomyelitis (EAE), Th17 cells are critical for the develop-
ment of autoimmune pathology. In this mouse model, Th17
cells promote inflammation in the central nervous system
(CNS), ultimately leading to paralysis (Komiyama et al., 2006;
Reboldi et al., 2009).
Because Th cells are so important, both in combating
and causing disease, elucidating the mechanisms that govern
their differentiation is of therapeutic interest. To develop into
Th effector cells, primed CD4+ T cells require a specific cytokine
milieu that is provided by innate immune cells. These cytokines
bias Th cell differentiation by activating master transcriptional
regulators that direct dedicated gene expression programs. In
this way, IFN-g and IL-12 direct Th1 cell development via the
transcription factor T-bet (Mullen et al., 2001), IL-4 enables Th2
cell development via GATA-3 (Zheng and Flavell, 1997), and
transforming growth factor-b (TGF-b), together with the proin-
flammatory cytokines IL-6 (Bettelli et al., 2006; Veldhoen et al.,
2006) or IL-21 (Korn et al., 2009), instruct Th17 cell differentiation
through retinoic acid receptor-related orphan receptor (ROR)
gt (Ivanov et al., 2006), RORa (Yang et al., 2008), and Batf
(Schraml et al., 2009).
Besides antigen-dependent signals provided by the T cell
receptor (TCR) complex and the CD4 coreceptor, naive Th cells
require costimulation to drive their expansion and survival. In this
context, the contribution of tumor necrosis factor (TNF) receptor
family members and their membrane-bound TNF-related ligands
is important (Watts, 2005). During infection, these molecules
facilitate the clonal expansion of primed T cells, their accumula-
tion at tissue sites, and the formation of memory cells, primarilyImmunity 38, 53–65, January 24, 2013 ª2013 Elsevier Inc. 53
Immunity
CD27 Inhibits Th17 Cell Functionby prosurvival signaling. TNF receptor family members also
provide signals that bias Th cell differentiation, but it is unclear
whether they influence Th cell differentiation by directly altering
the transcriptional programof primedCD4+ T cells or by support-
ing CD4+ T cell survival in a specific cytokine environment
(Watts, 2005).
Naive CD4+ T cells express the TNF receptor family member
CD27 and acquire related receptors at the priming or effector
stage. CD70, the ligand for CD27, is found on activated dendritic
cells (DCs) and lymphocytes (Borst et al., 2005). It is also consti-
tutively expressed on certain antigen-presenting cells in the
thymic medulla and the intestinal epithelium (Borst et al., 2005;
Laouar et al., 2005). The CD27 and CD70 costimulatory pathway
supports CD4+ and CD8+ T cell responses by providing survival
signals (Hendriks et al., 2000, 2003), but it can also influence
the CD4+ T cell response in a qualitative manner. Several
studies have demonstrated that interactions between CD27
and CD70 drive Th1 cell differentiation (Arens et al., 2001; Soares
et al., 2007; van Oosterwijk et al., 2007; Xiao et al., 2008).
Furthermore, CD70 is present on a gut-resident DC population
that is critical for the generation of Th17 cells (Atarashi et al.,
2008), alluding to a role for CD27 costimulation in Th17 cell
differentiation.
In this study, we have addressed the impact of the CD27 and
CD70 costimulatory pathway on Th17 cell differentiation. By
using CD27-deficient mice, newly developed CD70-deficient
mice, and Cd70 transgenic mice, we demonstrate that the
CD27 and CD70 costimulatory pathway suppressed EAE devel-
opment by reducing the generation of Th17 effector cells and
their infiltration into the CNS. CD27 signaling repressed Th17
effector cell differentiation, despite normal RORgt induction. It
inhibited Il17a gene transcription via the JNK pathway and via
epigenetic effects and also suppressed CCR6 expression via
the JNK pathway. These results demonstrate that CD27 costi-
mulation specifically impairs Th17 effector cell function and
thereby ameliorates associated autoimmunity.
RESULTS
EAE Is Exacerbated in the Absence of CD27 or CD70
and Ameliorated upon Sustained CD27 Costimulation
In the EAE model, myelin oligodendrocyte glycoprotein (MOG)-
specific CD4+ T cells are primed in secondary lymphoid organs
in response to MOG35-55 peptide injection and subsequently
enter theCNSas autoreactive effector cells that cause aprogres-
sive paralysis. To test the contribution of CD27 costimulation to
the development of this Th17 cell-dependent autoimmune
disease, we made use of Cd27/ mice and newly generated
Cd70Cre/Cre mice (see Supplemental Experimental Procedures
available online). InCd70Cre/Cre mice, theCd70 gene was disrup-
ted by insertion of the Cre gene into the Cd70 locus, resulting in
complete abrogation of CD70 expression (Figure S1). After EAE
was induced in wild-type (WT), Cd27/, and Cd70Cre/Cre mice,
mice were monitored for clinical signs of autoimmunity over
a period of 20 days. Disease was significantly exacerbated in
Cd27/ and Cd70Cre/Cre mice compared to WT, as manifested
by more severe disease symptoms (Figure 1A and Table S1)
and reduced overall survival (Figure 1B). These results sug-
gested an effect of CD27 costimulation on the generation of54 Immunity 38, 53–65, January 24, 2013 ª2013 Elsevier Inc.Th17 cells. We therefore analyzed IL-17 and IFN-g production
by MOG-specific CD4+ T cells in the spleen at day 6 after EAE
induction. The frequency of IL-17+CD4+ T cells was significantly
higher in Cd27/ mice than in WT mice whereas the frequency
of IFN-g+CD4+ T cells was similar between the two groups
(Figure 1C). IL-17-producing cells were CD44hi, indicating that
they had recognized antigen.
EAE was more severe in the absence of CD27 costimulation,
so sustained CD27 costimulation was expected to dampen
disease severity. To test this, EAE was induced in mice that
constitutively express CD70 on conventional DCs (Keller et al.,
2008). In these CD11c-Cd70tg mice, disease was significantly
less severe than in control mice (Figure 1D). Within the Cd70tg
group, 50% of mice were almost completely protected from
disease (score < 1). In the remaining 50%, disease progression
was delayed but reached a similar severity as in control mice
(Figures 1E and S2A). Histological analysis showed that infil-
trating leukocytes were almost absent in the spinal cords of
Cd70tg mice at day 10, whereas control mice showed a striking
infiltration into cervical, lumbar, and sacral regions. At day 20,
leukocyte infiltration was also observed in the spinal cords of
Cd70tg mice that displayed progressive disease (Figure S2B
and data not shown). Of note, CD70 expression was not
detected in the brain or spinal cord of any groups of mice (data
not shown). The combined data suggest that the CD27 and
CD70 costimulatory pathway inhibits the generation of Th17
cells and thereby attenuates the development of EAE.
Decreased Numbers of Th17 Cells in Cd70tg Mice
CD4+ T cells that had infiltrated theCNS (brain and spinal cord) of
control and Cd70tg mice were analyzed for IL-17 and IFN-g
production at day 20 after EAE induction. For this evaluation,
Cd70tg mice were separated into the two groups that exhibited
progressive (score > 1) or nonprogressive (score < 1) disease.
Most strikingly, in Cd70tg mice with nonprogressive disease,
the CNS contained almost no IL-17+CD4+ T cells and signifi-
cantly reduced numbers of IFN-g+CD4+ T cells (Figure 2A).
In Cd70tg mice with progressive disease, the CNS did contain
IL-17+CD4+ T cells, but significantly less than in control mice in
terms of frequency and absolute number (Figure 2A). It is
possible that these mice experienced a more Th1 cell-biased
EAE, because the frequency of IFN-g+CD4+ T cells was greater
than in control mice (Figure 2A). We noted that IL-17 and IFN-g
production by CNS-infiltrating lymphocytes in WT and Cd27/
mice of similar disease severity was not different (data not
shown). CD4+ T cells in the spleen of Cd70tg mice were also
examined for IL-17 and IFN-g production at day 20 after EAE
induction (Figure 2B). The frequency of IL-17+CD4+ T cells was
significantly reduced in Cd70tg mice as compared to control
mice, whereas the frequency of IFN-g+CD4+ T cells was not
consistently different between the two groups.
CD4+ T cells were also analyzed earlier, at day 10 after EAE
induction (Figure 2C). In the CNS, frequency and absolute
number of IL-17+CD4+ T cells were lower in Cd70tg mice than
in control mice, whereas frequency and absolute number of
IFN-g+CD4+ T cells were significantly higher. In the spleen, the
frequency of IL-17+CD4+ T cells was also lower in Cd70tg mice
than in control mice, whereas the frequency of IFN-g+ cells
was similar (Figure 2D). Overall, these results demonstrate
01
2
3
4
0 5 10 15 20
D
is
ea
se
 s
co
re
D
Time (days)
*
Cd70tg
Control
*
*
*
0
1
2
3
4
0 5 10 15 20
Time (days)
D
is
ea
se
 s
co
re
Cd27-/-
WT
Cd70Cre/Cre
A C
IFN-
WT
Cd27-/-
MOG35-55 (µg/ml)
0 1 10 100
0 101 102 103
0
102
103
104
0 101 102 103
0
102
103
104
0 101 102 103
0
102
103
104
0 101 102 103
0
102
103
104
WT Cd27-/-
0.11 0.15
0.56 1.29
CD44
IL
-1
7
*
No 
peptide
MOG35-55
Cy
to
kin
e+
 
(%
)
IL-17
0 1 10 100
*
*
*
0
0.2
0.4
0.6
0.8
1.0 1.5
1.0
0.5
0
Time (days)
B
Su
rv
iva
l (%
)
WT
0 5 10 15 20
100
80
60
40
20
0
Cd27-/-
Cd70Cre/Cre
E
0 5 10 15 20
100
80
60
40
20
0
M
ic
e 
> 
sc
or
e 
1 
(%
)
Time (days)
Cd70tg
Control
***
Figure 1. EAE Is Exacerbated in CD27- and CD70-Deficient Mice and Ameliorated in Cd70tg Mice
(A–C) EAEwas induced inWT (n=17),Cd27/ (n = 16), andCd70Cre/Cre (n =7)mice andmiceweremonitoreddaily for clinical signs of EAEover aperiod of 20days.
(A) Disease development as diagnosed by defined scores.
(B) Overall survival. Mice with a disease score of 4 or more were sacrificed and a survival curve was generated.
(A and B) p < 0.05 for Cd27/ (indicated by #) and Cd70Cre/Cre (indicated by x) mice as compared to WT.
(C) Cytokine production by CD4+ T cells in the spleen. Splenocytes were isolated at day 6, restimulated with MOG35-55 peptide, and analyzed for IL-17 and IFN-g
production by intracellular staining. Contour plots depict IL-17 and CD44 expression in gated CD4+ T cells. Numbers represent percentage of cells in the
indicated gates. Graphs indicate the percentage of cytokine-expressing cells among gated CD4+ T cells. Data are from two experiments with WT (n = 9) and
Cd27/ (n = 10) mice, *p < 0.05.
(D and E) EAE was induced in control Cd27+/ (n = 13) and Cd70tg;Cd27+/ (n = 10) mice and mice were monitored daily for clinical signs of EAE over a period
of 20 days.
(D) Disease development in both groups, *p < 0.05.
(E) Frequency of disease severity. The percentage of mice with a disease score greater than 1 was plotted, ***p < 0.001.
See also Figure S2 and Table S1. Statistical significance was determined by Mann-Whitney U rank test (A, C, and D) and Log rank test (B, E).
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Figure 2. Reduced Th17 Cell Generation in
Cd70tg Mice with EAE
(A) Cytokine production by CD4+ T cells in the CNS
at day 20 after EAE induction. CNS-infiltrating
cells were isolated, stimulated with PMA and
ionomycin, and analyzed for IL-17 and IFN-g
production by intracellular staining. Contour plots
depict IL-17- and IFN-g-producing cells among
gated CD4+ T cells of control Cd27+/ mice and
Cd70tg;Cd27+/ mice with progressive (score > 1)
and nonprogressive (score < 1) disease. Shown
are mice with disease scores of 2 (left plot),
2 (middle), and 0.5 (right). Numbers depict the
percentage of cells in each quadrant. Graphs
indicate the percentage and absolute number (#)
of cytokine-expressing cells among gated CD4+
T cells. Data are from two experiments with control
(n = 7), Cd70tg score > 1 (n = 4), and Cd70tg
score < 1 (n = 4) mice.
(B) Cytokine production by CD4+ T cells in the
spleen at day 20 was analyzed as described in
Figure 1C. Graphs depict data fromWT (n = 5) and
Cd70tg (n = 3) mice.
(C and D) Cytokine production by CD4+ T cells in
the CNS (C) and spleen (D) at day 10. Analysis
was done as outlined in (A) and (B). Data are from
two experiments with control (n = 9) and Cd70tg
(n = 6) mice.
Statistical significance was determined by Mann-
Whitney U test, *p < 0.05.
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generation of Th17 cells in the lymphoid organs and the associ-
ated autoimmunity in the CNS.
Decreased CCR6 Expression but Normal RORgt
Expression in Th17 Cells of Cd70tg Mice
To examine whether constitutive CD27 signaling in vivo affected
Th17 cell differentiation commitment of CD4+ T cells, we exam-
ined expression of the lineage-determining transcription factor
RORgt in the EAE model. Control and Cd70tg CD4+ T cells from
CNS and spleen were analyzed for expression of RORgt at
day 10. In both tissues, RORgt was expressed in IL-17+IFN-g
and IL-17+IFN-g+ cells whereas IL-17 cells were largely RORgt
negative (Figures 3A and 3B). Expression of RORgt was similar
between control and Cd70tg mice, indicating that constitutive56 Immunity 38, 53–65, January 24, 2013 ª2013 Elsevier Inc.CD27 stimulation did not alter RORgt
expression. We additionally examined
the expression of CCR6, a chemokine
receptor expressed on Th17 cells that is
involved in homing to inflamed tissues
(Reboldi et al., 2009). Among CD4+
T cells of control mice, CCR6 expression
was most pronounced on IL-17+IFN-g
cells. In Cd70tg mice, however, this was
markedly reduced (Figure 3C). CCR6
expression on IL-17IFN-g+CD4+ T cells
was also moderately reduced, but it was
normal in IL-17IFN-gCD4+ T cells.
These data indicate that CD27 costimula-
tion does not affect Th17 cell lineagecommitment by modulating RORgt expression but inhibits IL-
17 and CCR6 expression in differentiating Th17 cells despite
normal RORgt expression.
CD27 Signaling Impedes Th17 Cell Differentiation
To determine whether CD27 signaling directly impacted CD4+
effector T cell differentiation, we employed in vitro Th cell
differentiation cultures. Purified naive CD4+ T cells (CD4+
CD25CD44lo) from spleens ofWT andCd27/mice were stim-
ulatedwith CD3mAb in presence of irradiated splenocytes. Th17
cell differentiation was induced with TGF-b, IL-6, and mAb
against IFN-g and IL-4 and for Th1 cell differentiation with
IL-12 and IL-4 mAb. To stimulate CD27, we used a previously
validated agonistic recombinant CD70 protein (FcCD70) (Peper-
zak et al., 2010). After 4 days, cells were counted and
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Figure 3. CD27 Signaling Reduces CCR6 but Not RORgt Expression in Th17 Cells of Mice with EAE
EAEwas induced in controlCd27+/ andCd70tg;Cd27+/mice and the spleen and CNSwere harvested at day 10. CNS-infiltrating lymphocytes and splenocytes
were restimulated in vitro as described in Figure 2 and analyzed by intracellular staining.
(A and B) RORgt expression. Histograms depict RORgt expression on IL-17+IFN-g (bold black line, unfilled), IL-17+IFN-g+ (light gray, filled), IL-17IFN-g+ (gray
line, unfilled), and IL-17IFN-g (dark gray, filled) cells in control and Cd70tg mice from the CNS (A) and the spleen (B). Bar graphs depict the percentage of
RORgt+ cells among the gated population indicated.
(C) CCR6 expression. Histograms depict the expression of CCR6 on control (gray line) or Cd70tg (black line) cytokine-producing cells as indicated. Bar graphs
depict the percentage of CCR6+ cells among the gated population indicated. Results are comprised from one experiment with littermate control (n = 7) and
Cd70tg (n = 3) mice.
Statistical significance was determined by the Student’s t test, *p < 0.05.
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Figure 4. CD27 Signaling Impairs Th17 Cell
Differentiation In Vitro
Naive CD4+ T cells (CD4+CD25CD44lo) were
purified from spleens of WT or Cd27/ mice and
cultured for 4 days with irradiated splenocytes
under Th17 or Th1 cell differentiation conditions, in
the presence or absence of 1 mg/ml agonistic re-
combinant CD70 (FcCD70). After culture, cells
were stimulated with PMA and ionomycin and
analyzed for IL-17 and IFN-g by intracellular
staining.
(A) Contour plots depict IL-17- and IFN-g-
producing cells. Numbers indicate the percentage
of cells in the quadrants.
(B) Graphs of the percentage and number of IL-17+
cells per well. Data are pooled from three experi-
ments with duplicate cultures (n = 6).
(C and D) In separate experiments, cells were
costimulated with FcCD70 and IL-2Ra mAb (PC-
61 mAb, 10 mg/ml) was added to the cultures as
indicated. Graphs depict the percentage (C) and
number (D) of cells per well that produce IL-17.
Data are pooled from two experiments with
duplicate cultures (n = 4).
Statistical significance was determined by Mann-
Whitney U test, *p < 0.05, **p < 0.01. See also
Figure S3.
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CD27 Inhibits Th17 Cell Functionexamined for IL-17 and IFN-g production (Figures 4A and 4B).
Strikingly, deliberate CD27 costimulation with FcCD70 strongly
reduced the yield of IL-17+CD4+ T cells fromWT Th17 cell differ-
entiation cultures. It did not affect the yield of IL-17+CD4+
T cells from Cd27/ cultures, confirming the specificity of
this reagent. CD27 costimulation with FcCD70 did not affect
the development of IFN-g-producing cells in either Th17 or
Th1 cell differentiation cultures (Figure 4A), nor did it impact
Th2 cell differentiation (Figure S3A). Apart from reducing the yield
of IL-17+CD4+ T cells, CD27 costimulation with FcCD70 also
reduced the expression of IL-17 in individual cells (Figure S3B).
When the T cells were provided with CD28 costimulation
instead of irradiated antigen-presenting cells, CD27 costimula-
tion similarly reduced the yield of Th17 cells (Figure S3C).
CD27 costimulation also reduced IL-17F and CCR6 protein
expression in Th17 cell differentiation cultures (Figures S3D
and S3E). Furthermore, even upon delayed addition into the
culture, FcCD70 still greatly reduced the development of Th17
cells (Figure S3F), indicating that CD27 costimulation inhibits
IL-17 expression without affecting early Th17 cell differentiation
signals.
CD27 signaling induces the production of IL-2 (Peperzak et al.,
2010), which is known to inhibit Th17 cell development (Laurence
et al., 2007). Therefore, we tested whether CD27 impeded Th17
cell differentiation via the IL-2R pathway by using a blocking
mAb directed to the IL-2 receptor a chain. Blockade of the inter-
action between IL-2 and IL-2R increased the percentage of
IL-17+ cells in culture (Figure 4C) but did not significantly affect58 Immunity 38, 53–65, January 24, 2013 ª2013 Elsevier Inc.the number of IL-17+ cells generated (Fig-
ure 4D). CD27 costimulation with FcCD70
still impeded the generation of Th17 cells
when the IL-2R pathway was blocked(Figure 4D), indicating that CD27 costimulation did not inhibit
Th17 cell differentiation via the IL-2R pathway.
CD27 Signaling Does Not Affect Th17 Cell Commitment
but Impedes IL-17, IL-17F, and CCR6 Transcription
To understand the mechanism by which CD27 costimulation in-
hibited Th17 cell differentiation, we determined its impact on
mRNA expression of a wide array of transcription factors, cyto-
kines, and cytokine and chemokine receptors associated with
Th cell lineage differentiation. As found for protein expression,
mRNA expression of IL-17, IL-17F, and CCR6 was dramatically
reduced in Th17 cells upon CD27 costimulation, whereas
mRNA expression of RORgt was not affected (Figure 5A). The
mRNA expression of other master transcriptional regulators
(RORa, Batf, T-bet, GATA-3, Bcl-6, or Blimp) were also not
affected by CD27 costimulation (Figure 5A), indicating that
CD27 signaling did not alter CD4+ T cell differentiation by globally
affecting Th cell commitment. IL-22 or IL-23 receptor (IL-23R)
mRNA expression was not affected, whereas IL-21 and IL-4
mRNA expression was increased upon CD27 costimulation (Fig-
ure 5A). Although this suggested a possible skewing toward the
T follicular helper (Tfh) cell pathway, CXCR5 mRNA expression
was not affected, IL-4 protein could not be detected (data not
shown), and Tfh cell development was not dependent on CD27
in an in vivo model of OVA and alum challenge (data not shown).
Because early activation of the transcription factor STAT-3 is
important for Th17 cell differentiation (Zhou et al., 2007), we
examined the phosphorylation status of STAT-3. Cells cultured
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Figure 5. CD27 Signaling Inhibits Transcrip-
tion of Il17a, Il17f, andCCR6Genes but Does
Not Affect Lineage Commitment of Th17
Cells
(A and D) CD4+ T cells were cultured under Th17
cell differentiation conditions in presence or
absence of FcCD70. After 4 days, triplicate cell
samples were analyzed by quantitative PCR for
transcription of the indicated genes. Messenger
RNA expression was normalized to 18S ribosomal
RNA. Data are representative of two experiments.
Statistical significance was determined with the
Student’s t test, *p < 0.05, **p < 0.01.
(B and C) Cells were cultured under Th17 cell
differentiation conditions in the presence (dotted
line) or absence (solid line) of FcCD70, or with CD3
mAb as a control (shaded histogram) and analyzed
for STAT-3 phosphorylation (B) after 20 hr or for
Foxp3 (C) expression after 4 days of culture.
Histograms are representative of two (B) or four (C)
experiments.
See also Tables S2–S4.
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STAT-3 expression than control cells, but CD27 costimulation
with FcCD70 did not alter pSTAT-3 expression (Figure 5B). The
transcription factor Foxp3 negatively regulates the differentiation
of Th17 cells, promoting regulatory T (Treg) cell development
instead (Zhou et al., 2008). FcCD70 did not affect Foxp3 expres-
sion in developing Th17 cells (Figure 5C), indicating that CD27
costimulation did not skew their differentiation toward the Treg
cell lineage.
Collectively, these data indicate that the CD27 signaling
pathway selectively impedes IL-17, IL-17F, and CCR6 expres-
sion by developing Th17 cells at the transcriptional level, without
altering their overall developmental program.
CD27 Inhibits IL-17 and CCR6 Expression by Th17 Cells
via the JNK Pathway
To garner further insight into the molecular mechanism by which
CD27 modulates Th17 effector cell development, gene expres-
sion profiling was performed on cells that had been cultured
for 24, 48, or 96 hr under Th17 cell differentiation conditions in
the presence or absence of FcCD70. CD27 costimulation
significantly upregulated Lymphotoxin-a (Lta) gene expressionImmunity 38, 53–6at both the 24 and 48 hr time points
(Tables S2 and S3). Nevertheless, Lta
receptor agonist or antagonist reagents
had no effect on IL-17 expression in these
cultures (data not shown). Among the
most differentially expressed molecules
were also IL-2, which had already been
excluded as a major factor (Figure 4D),
and cytokine-inducible SH2 (CIS) protein,
typically considered a suppressor of
cytokine signaling (Matsumoto et al.,
1997). It was unlikely that CIS impaired
the cytokine responsiveness of devel-
oping Th17 cells under conditions of
CD27 costimulation, because STAT-3activation was not affected (Figure 5B) and the delayed addition
of FcCD70 also inhibited IL-17 production (Figure S4C).
At the 96 hr time point, a number of genes were differentially
expressed as a result of CD27 costimulation including IL-17
and CCR6 (Table S4). Other differentially expressed genes
included Batf-3, Crem, and Atf-3 that belong to the Crem and
Atf family of transcription factors. These molecules were of
interest because they can form dimers with the JNK target mole-
cule c-Jun and thusmodulate gene expression (Thompson et al.,
2009). Induction of Batf-3, Crem, and Atf-3 mRNA expression
upon CD27 costimulation was confirmed by q-PCR (Figure 5D).
This finding suggested that CD27 might modulate gene expres-
sion in developing Th17 cells through JNK, one of its main down-
stream effector molecules (Akiba et al., 1998). The identification
of CIS as a CD27-target gene supported this idea, because CIS
not only acts as a cytokine suppressor but also potently stimu-
lates JNK and ERK signaling in CD4+ T cells, downstream of
the TCR and CD28 (Li et al., 2000).
To determine whether CD27 costimulation activated the JNK
pathway, developing Th17 cells were analyzed for JNK phos-
phorylation status. Expression of phosphorylated (p)-JNK was
low in differentiating Th17 cells in the first 24 hr of culture but5, January 24, 2013 ª2013 Elsevier Inc. 59
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to the cultures significantly enhanced p-JNK expression over
control (Figure 6A). To test the possible involvement of JNK
activity in Th17 cell differentiation, the cultures were performed
in the presence or absence of a peptidic JNK inhibitor (D-
JNKI1) (Bonny et al., 2001). JNK inhibition dramatically enhanced
IL-17 and CCR6 expression in the developing Th17 cells (Fig-
ure 6B), indicating that the JNK pathway controls Th17 effector
cell differentiation. JNK inhibition had a significantly greater
effect on IL-17 and CCR6 expression in CD27-costimulated cells
than in control cells (Figure 6B). Furthermore, JNK inhibition
facilitated IL-17 mRNA expression in CD27-costimulated cells
(Figure 6C). This indicates that CD27 signaling suppresses
IL-17 and CCR6 expression at least in part by means of JNK
activity. In the same setting, inhibition of the p38 MAP kinase
pathway that is also activated by CD27 (Guikema et al., 2004)
had no significant effect on IL-17 and CCR6 expression in devel-
oping Th17 cells (Figure 6D). In CD27-costimulated cells, p38
inhibition reduced rather than enhanced CCR6 expression (Fig-
ure 6D). This indicates that p38 was not responsible for the
CD27-mediated suppression of CCR6 expression that we had
observed in developing Th17 cells. We conclude that CD27
costimulation inhibits the development of Th17 effector cell func-
tion at least in part via the JNK pathway that can strongly
suppress IL-17 and CCR6 expression.
CD27 Signaling Induces Epigenetic Modifications
and Silences Il17a Gene Expression
Given that CD27 repressed IL-17 expression at the transcrip-
tional level, we considered that epigenetic mechanisms might
also be at play. The Il17a gene in mice is not particularly rich in
CpG residues but histones are dynamically modified at this
gene locus during Th cell differentiation (Akimzhanov et al.,
2007). We examined the effect of CD27 costimulation on the
histone modification status of the Il17a and Ifng promoters.
Chromatin immunoprecipitation (ChIP) by antibodies specific
for total H3, H3K4me3, H3K14Ac, H3K27me3, and H3K9me2
were performed from cells cultured for 4 days under Th17
cell differentiation conditions in the presence or absence of
FcCD70. H3K4me3 and H3K14Ac marks are generally regarded
as permissive modifications for gene transcription, whereas
H3K27me3 and H3K9me2modifications repress gene transcrip-
tion (Wilson et al., 2009). Analysis by q-PCR after ChIP revealed
a more than 2-fold increase in repressive H3K27me3 marks at
the Il17a gene promoter and a consistent decrease in acetylation
of K14 in CD27-stimulated cells (Figure 7A). In contrast, these
modifications were unaltered at the Ifng promoter (Figure 7B).
To determine the location of these modifications at the Il17a
locus, next-generation sequencing of H3K27me3 ChIP frac-
tions was performed. This analysis confirmed an increase in
H3K27me3 marks at the Il17a gene promoter directly proximal
to the transcription start site and also revealed an increase in
these marks toward the 30 end of the gene (Figure 7C). The
Il17f and Ccr6 gene loci were not enriched for this suppressive
mark (results not shown).
The histone modifications that took place at the Il17a locus in
response to CD27 costimulation are indicative of a ‘‘closed’’
chromatin structure, which is unfavorable for gene transcription.
To test whether epigenetic changes contributed to the repres-60 Immunity 38, 53–65, January 24, 2013 ª2013 Elsevier Inc.sion of IL-17 expression by CD27 costimulation, we used
5-azacytidine (5-aza). This is a DNA demethylating agent that
produces a more ‘‘open’’ chromatin conformation (Christman,
2002). The compound significantly restored the capacity of
CD27-stimulated cells to produce IL-17, whereas it had no effect
on IL-17 production in control cultures and did not affect IFN-g
production (Figure 7D). This finding further supported that
CD27 signaling silences Il17a gene transcription at least in part
by epigenetic effects. The collective data indicate that CD27
downregulates IL-17 production at the level of gene transcription
not only via JNK activation and associated transcriptional regu-
lation but also by epigenetic mechanisms.
DISCUSSION
In this study, we have demonstrated that CD27 costimulation
inhibited the generation of competent Th17 effector cells by
repressing IL-17, IL-17F, and CCR6 expression in developing
Th17 cells. CD27 costimulation ameliorated Th17 cell-depen-
dent autoimmunity in the EAEmodel, most probably by reducing
the amount of proinflammatory IL-17 produced by Th17 cells in
the CNS, but also by reducing CCR6-dependent infiltration of
Th17 cells into the brain (Reboldi et al., 2009). CD27 signaling
repressed Th17 effector cell function, despite the normal induc-
tion of transcription factors generally associated with Th17 cell
commitment. Contrary to our findings, CD70 blocking in vivo in-
hibited EAE in SJL mice immunized with PLP139-151 peptide (Na-
kajima et al., 2000). This discrepancy may be due to the genetic
background of the mice, use of CD70 blocking mAb rather than
gene-targeted mice, or a combination of these. In our study, use
of in vivo and in vitro models and different ways to stimulate or
disrupt CD27 costimulation consistently demonstrated that
CD27 signaling impeded IL-17 and CCR6 expression in differen-
tiating Th17 cells.
Under which conditions might this novel pathway that impairs
Th17 effector cell function be operational? In mouse and human,
CD27 is constitutively expressed on the great majority of naive
and activated CD4+ and CD8+ T cells, but its engagement is
conditional upon the expression of CD70, which is tightly
controlled. CD70 is expressed by DCs, B cells, and T cells, but
only when they have been activated by antigen (Borst et al.,
2005). CD70 expression is therefore an exquisite hallmark of
acute or chronic immune activation. Our data indicate that
CD27 costimulation inhibits Th17 cell development in the EAE
model during the priming phase. However, this pathway may
play an ongoing regulatory role in other contexts where immune
activation does not subside.
Intriguingly, a prominent subset of DCs in the lamina propria of
the mouse gut constitutively expresses CD70 (Atarashi et al.,
2008; Laouar et al., 2005), most probably as a consequence of
chronic stimulation by the rich microbial flora at this location.
This CD70+ DC population efficiently promotes Th17 cell devel-
opment by producing high amounts of IL-6 and IL-23 (Atarashi
et al., 2008), in seeming contradiction with our finding that
CD27 signaling inhibits Th17 effector cell function. Whether the
stimulatory or inhibitory role of CD70+ DCs in Th17 cell develop-
ment prevails may depend on whether the DC directly primes
the CD4+ T cell or has a bystander effect by secreting cytokines.
The effect of CD70 on the DC may also depend on whether the
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Figure 6. CD27 Inhibits IL-17 and CCR6 Expression via JNK Signaling
Th17 cell differentiation cultures were performed in the presence or absence of FcCD70.
(A) At 24, 48, or 96 hr, phosho(p)-JNK expression was analyzed by flow cytometry. The histogram shows control (secondary antibody) staining of cells cultured
without (dark gray, filled) or with (light gray, filled) FcCD70 and staining with a p-JNK-specific primary antibody and secondary antibody on cells cultured without
(solid black line) orwith (dotted line) FcCD70at the48hr timepoint.Graphdepicts thepercentage of p-JNK+cells.Data are pooled from threeexperiments (n=5–7).
(B) Cells were cultured in the presence of the JNK inhibitor D-JNKI1 (3 mM) or vehicle control (). At day 4, IL-17 and CCR6 expression was analyzed by flow
cytometry as shown in the dot plots, with percentage of cells indicated in the quadrants. Graphs depict the fold increase in IL-17- or CCR6-expressing cells
because of D-JNKI1 addition. Data are pooled from four experiments (n = 6).
(C) Cells cultured as in (B) were analyzed for IL-17 mRNA expression by quantitative PCR, with normalization to 18S ribosomal RNA. Results are pooled from two
experiments with a total of five separate cultures.
(D) Cultures were performed in the presence of p38MAP kinase inhibitor SB203580 (1 mM) or vehicle control () and IL-17 and CCR6 expression was analyzed as
indicated in (B). Data are pooled from two experiments (n = 3–4).
Statistical significance was determined by Mann-Whitney U test, *p < 0.05, **p < 0.01.
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Figure 7. CD27 Signaling Epigenetically
Silences the Il17a Gene
CD4+ T cells were cultured under Th17 cell differ-
entiation conditions in the presence or absence of
FcCD70 for 4 days.
(A–C) Chromatin immunoprecipitations (ChIP)
were performed from 5 3 106 cells per sample
with antibodies specific for total H3, H3K4me3,
H3K14Ac, H3K27me3, and H3K9me2.
(A and B) Isolated DNA was used as a template for
quantitative PCR with primers specific for the Il17a
gene promoter (A) or the Ifng promoter (B). Signals
from ChIP of modified histone H3 were standard-
ized to signals obtained from ChIP of total H3
(recovery was between 3% and 10%). Values from
cells cultured in the presence of FcCD70 were
normalized to values in its absence to allow for
interexperimental comparison. Results are from
three experiments.
(C) H3K27me3 ChIP fractions were additionally
used for next-generation sequencing. The graph
shows the distribution of the H3K27me3 signal
(normalized read count) over the Il17a locus, as
detected in cells cultured without (black) or
with (gray) FcCD70. The gene region presented
includes a 1 kb promoter region (black line), the
transcriptional start site (TSS), the coding region
(gray line), and 30 untranslated region (UTR).
(D) Genomic demethylation restores IL-17 pro-
duction by CD27-stimulated cells. The demethy-
lating agent 5-azacytidine was added for the last
16 hr of Th17 cell differentiation culture. Contour
plots depict IL-17- and IFN-g-producing cells. The
graph depicts the fold increase in percentage of
IL-17+ cells in the presence of 5-aza in cultures
with or without FcCD70. Data are pooled from four
experiments (n = 9–10).
Statistical significance was determined by Mann-
Whitney U test, ***p < 0.001.
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CD27 Inhibits Th17 Cell Functionuncommitted CD4+ T cells express CD27. It is notable that
among conventional CD4+ T cells (Pepper et al., 2010), regula-
tory T cells (Koenen et al., 2008), and gd T cells (Ribot et al.,
2009), the IL-17-producing cells lack CD27 expression. We
have observed a CD27-negative IL-17+CD4+ T cell population
in the lamina propria of both WT and Cd70Cre/Cre mice (data
not shown), indicating that CD27 is not downregulated on these
cells resulting from interaction with CD70. Rather, it suggests
that lack of CD27 expression allows certain naive CD4+ T cells
to escape from the suppressive effects of CD27 costimulation
and to effectively differentiate into Th17 cells.
CD27 may also impede IL-17 production by human CD4+
T cells. In non-Hodgkin lymphoma where CD70 is expressed
on malignant B cells, Th17 cell differentiation was inhibited in
a CD70-dependent manner (Yang et al., 2009). This pathway
also appears to strongly favor Treg cell expansion and/or
survival (Yang et al., 2009). Furthermore, CD70 overexpression
is a hallmark of chronic diseases such as rheumatoid arthritis
and systemic lupus erythematosus (Lee et al., 2007; Oelke62 Immunity 38, 53–65, January 24, 2013 ª2013 Elsevier Inc.et al., 2004). It is possible that CD27 plays
an important role in maintaining the
balance of pathogenic Th17 cells andtolerogenic Treg cells during chronic immune activation in
humans.
Costimulatory molecules are often viewed as mere amplifiers
of the immune response, but there is abundant evidence that
TNF receptor family members such as OX40 and 4-1BB can
have an impact on effector differentiation of CD4+ T cells (Ishii
et al., 2010; So et al., 2008; Watts, 2005). The CD27 and CD70
costimulatory pathway can promote Th1 cell development in
an IL-12-independent manner (Soares et al., 2007). However,
thus far it is not clear whether this is a direct effect of costimula-
tory receptor signaling into CD4+ T cells or an indirect effect of
keeping CD4+ T cells alive in a certain (cytokine) environment.
We show here that CD27 costimulation directly influences
Th17 cell function by dedicated molecular mechanisms. We
also provide evidence that CD27 signaling acts directly in
a cell-intrinsic manner to modify effector function of a Th cell
lineage. CD27 signaling led to epigenetic silencing of the Il17a
locus and IL-17 production was partially restored by the DNA
demethylating agent 5-aza. This indicates that CD27 signaling
Immunity
CD27 Inhibits Th17 Cell Functionsuppresses Il17a gene expression at least in part by inducing
stable marks on histones and possibly on the DNA itself. This
is expected to confer resistance to the acquisition of Th17
effector cell function in the costimulated cells and their progeny.
Importantly, the H3K27me3 epigenetic profile at the Il17f and
Ccr6 loci was not obviously altered in cells that had received
CD27 costimulation (data not shown). Possibly, CD27 costimula-
tion modified the epigenetic status of these loci in another way,
or repressed transcription of these genes solely by nonepige-
netic mechanisms.
We also found that CD27 made use of the JNK pathway to
suppress IL-17 and CCR6 expression, under the Th17 cell differ-
entiation conditions employed in vitro. The JNK pathway
potently suppressed IL-17 and CCR6 expression in developing
Th17 cells. JNK activates the c-Jun transcription factor, which
classically heterodimerizes with c-Fos to form the AP-1 tran-
scription factor complex (Hess et al., 2004). The proximal
promoter of the Il17a gene contains NFAT and AP-1 transcription
factor binding sites that cooperate to enhance the transcription
of this gene (Hermann-Kleiter et al., 2008; Liu et al., 2004).
Thus, it seems counterintuitive that inhibition of JNK activity
should prevent Il17a gene transcription. However, transcriptional
regulation by the JNK pathway is much more complex. c-Jun
belongs to a family of basic leucine zipper transcription factors
that can heterodimerize with members of the related Crem and
Atf family, to which Batf, Batf-3, Atf-3, and Crem belong. Upon
such heterodimerization, the DNA binding specificity can be
altered (Hai and Curran, 1991). The AP-1 nomenclature currently
refers to the entire collection of heterodimers that can have either
gene-activating or -repressive activity, depending on AP-1
complex composition and the cellular signaling context (Thomp-
son et al., 2009). Batf was recently shown to be essential for Th17
cell responses (Schraml et al., 2009), but it is possible that Batf-3,
Crem, and/or Atf-3, which are upregulated upon CD27 ligation,
form AP-1 complexes that can suppress Il17a and Ccr6 gene
expression. In support of this hypothesis, Atf-3 (Thompson
et al., 2009), Batf-3 (Hildner et al., 2008), and Crem (Solomou
et al., 2001) have all been shown to suppress Il2 gene transcrip-
tion induced by AP-1, NFAT, and NF-kB at the Il2 promoter. It is
possible that these factors play a similar regulatory role at the
Il17a gene promoter.
In conclusion, we have revealed that CD27 costimulation
impairs the acquisition of Th17 effector cell functions in differen-
tiating CD4+ T cells, despite unaltered expression of key regula-
tors of Th cell lineage commitment. This pathway proceeds
via JNK signaling and brings about specific epigenetic and
transcriptional changes. We propose that this exquisite regula-
tion is an important avenue for future research in Th cell
differentiation.EXPERIMENTAL PROCEDURES
Mice
C57BL/6, Cd27/, Cd70Cre/Cre, and CD11c-Cd70tg (Cd70tg)mice were bred
at the Netherlands Cancer Institute (NKI). Cd27/ mice were made on a 129/
Ola background and backcrossed to C57BL/6 mice for eight generations
(Hendriks et al., 2000). Cd70Cre/Cre mice in which CD70 expression is lost
due to deletion of exon 1 of the Cd70 gene were generated and validated as
described in Supplemental Experimental Procedures and depicted in Fig-
ure S1. Cd70Cre/Cre mice were backcrossed by speed congenics to a morethan 98% pure C57BL/6 background. By analogy with Cd27/ mice,
Cd70Cre/Cre mice developed normally and displayed a normal cellular distribu-
tion in all hematopoietic compartments. Previously described CD11c-Cd70tg
mice (Keller et al., 2008) were made on a C57BL/6 background and were used
as Cd27+/;Cd70tg, with Cd27+/ littermate controls. Animal experiments
were done according to national and institutional guidelines and were
approved by the experimental animal committee of the NKI.
EAE
All mice used in EAE experiments were 5–8 weeks of age. Mice were
immunized s.c. with 125 mg MOG35-55 peptide (MEVGWYRSPFSRVVHLY
RNGK, produced in-house) emulsified in Complete Freund’s Adjuvant (CFA)
supplemented with 40 mg/ml Mycobacterium tuberculosis H37RA (Difco
Laboratories). On the same day, mice received 150 ng of pertussis toxin
(List Biological Laboratories) diluted in 100 ml PBS i.v. Over a period of
20 days, mice were monitored daily for clinical signs of EAE and disease
was scored as follows: 0, no disease; 1, limp tail; 2, partial hind limb paralysis;
3, total hind limb paralysis; 4, forelimb paralysis; 5, moribund/dead. In accord
with institutional guidelines on animal ethics, micewere sacrificedwhen reach-
ing a disease score of 4.
Single-Cell Isolation
To isolate splenocytes, spleens were passed through 100 mMnylon mesh (BD)
and red blood cells were lysed in 0.14 M Na4Cl, 0.017 M Tris-HCl (pH 7.2) for
1 min at room temperature. Cells were resuspended in PBS containing bovine
serum albumin and counted on a CASY cell counter (Scha¨rfe). For lymphocyte
harvest from the brain and spinal cord (CNS), organs were passed through
100 mM nylon mesh. Cells were pelleted by centrifugation, resuspended in
a 33.75% v/v Percoll in PBS, and centrifuged at 5003 g for 12min, whereupon
the lymphocyte pellet was harvested.
Cell Cultures
Cells were cultured in IMDM supplemented with 8% FCS, penicillin,
streptomycin, and b-mercaptoethanol. For Th cell differentiation cultures,
naive CD4+ T cells (CD4+CD25CD44lo) were purified by flow cytometry and
cultured in wells coated with 2 mg/ml CD3 mAb (145-2C11) in the presence
of irradiated splenocytes, supplemented with 5 ng/ml recombinant human
TGF-b (R&D Systems), 20 ng/ml IL-6 (BD Biosciences), 4 mg/ml IFN-g mAb,
and 4 mg/ml IL-4 mAb (eBioscience) for Th17 cell differentiation, or with
5 ng/ml IL-12 (BD Biosciences) and 4 mg/ml IL-4 mAb for Th1 cell differentia-
tion. In some experiments, 5-azacytidine (Sigma) or blocking mAb directed
at the IL-2Ra chain (clone PC-61) was added at the indicated concentration.
To stimulate CD27 signaling, a fusion protein of the Fc portion of human
IgG1 and amino acids 41–195 representing the extracellular domain of mouse
CD70 (FcCD70) (Peperzak et al., 2010) were used. The p38a and p38b MAP
kinase inhibitor SB203580 (1 mM; Sigma) and the cell-permeable peptidic
D-JNKI1 JNK inhibitor (3 mM; Xigen S.A., Lausanne, Switzerland) were added
at the start of Th17 cell differentiation cultures.
Gene Array and Chromatin Immunoprecipitation
RNA for gene expression analysis was isolated by Trizol purification at 24, 48,
and 96 hr after the start of Th17 cell differentiation cultures. Samples were run
on the Illumina bead array platform allowing for quantitative analysis of mRNA
expression. ChIP from Th17 cell differentiation cultures (day 4) was performed
with antibodies to total H3 (AB1791), H3K4me3 (AB8580), H3K27me3
(AB4729), H3K9me2 (AB1220), all from Abcam and antibody to H3K14Ac
(06-911) from Millipore. In brief, DNA was cross-linked, cells were lysed
in RIPA buffer, and chromatin was sheered by sonication to fragments of
200–1,000 base pairs in length. Chromatin-bound DNA was eluted with the
JETquick spin kit (Genomed) and used as a template for q-PCR. Total input
DNA and eluted DNA from H3K27me3 immunoprecipitations were sequenced
on an Illumina HiSeq 2000. Sequences were aligned to a reference mouse
genome (NCBIm37, mm9) and ChIP data analysis was performed with custom
scripts in R (http://www.r-project.org).
Flow Cytometry, Intracellular Staining, and Quantitative PCR
These were performed according to standard procedures as outlined in the
Supplemental Experimental Procedures.Immunity 38, 53–65, January 24, 2013 ª2013 Elsevier Inc. 63
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Experimental Procedures.Statistical Analysis
The mean ± SEM is depicted in all graphs. For comparisons between two
groups, theMann-Whitney Rank U test was utilized. In the case where multiple
groups were compared, the p value was adjusted to take into account the
number of groups. The Logrank test was used where appropriate, and in
some cases, a Student’s t test was utilized.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and five tables and can be found with this article online at
http://dx.doi.org/10.1016/j.immuni.2012.09.009.ACKNOWLEDGMENTS
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